AstraZeneca: Tagrisso cancer drug gets EU approval
(CercleFinance.com) - AstraZeneca's Tagrisso has received a positive opinion from European health authorities for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
The drug, which had already been approved in the US and Brazil, will now have to be approved by the European Commission, which has the authority to approve medicines for the 28 EU member countries plus Iceland, Norway and Liechtenstein.
The decision only concerns patients with metastatic NSCLC whose tumours have EGFR mutations.
Approximately 10%-15% of patients in the US and Europe, and 30%-40% of patients in Asia have EGFR-mutated non-small cell lung cancer.
Novartis shares are currently up 1.5% at 5,066 pence on Friday, outperforming the STOXX Europe 600 Health Care index, which is down 0.9%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The drug, which had already been approved in the US and Brazil, will now have to be approved by the European Commission, which has the authority to approve medicines for the 28 EU member countries plus Iceland, Norway and Liechtenstein.
The decision only concerns patients with metastatic NSCLC whose tumours have EGFR mutations.
Approximately 10%-15% of patients in the US and Europe, and 30%-40% of patients in Asia have EGFR-mutated non-small cell lung cancer.
Novartis shares are currently up 1.5% at 5,066 pence on Friday, outperforming the STOXX Europe 600 Health Care index, which is down 0.9%.
Copyright (c) 2018 CercleFinance.com. All rights reserved.